for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dupixent and vaccines lift Sanofi first-quarter results

PARIS, April 28 (Reuters) - Sanofi confirmed its 2021 targets on Wednesday after it posted stronger-than-expected results in the first quarter, helped by sales of its star eczema treatment Dupixent and vaccines.

The French drugmaker, which stunned investors last year with a delay of a COVID-19 vaccine candidate it is developing with Britain’s GlaxoSmithKline, said it expected results of a phase II study evaluating the shot next month.

$1 = 0.8284 euros Reporting by Matthias Blamont; Editing by Christian Schmollinger

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up